Compare SBLK & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLK | LIVN |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | Greece | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2007 | 2015 |
| Metric | SBLK | LIVN |
|---|---|---|
| Price | $24.40 | $83.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $25.50 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 1.2M | 723.8K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | $11.56 | $9.79 |
| Revenue Next Year | N/A | $6.63 |
| P/E Ratio | ★ $47.06 | $202.63 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.72 | $41.02 |
| 52 Week High | $28.50 | $82.66 |
| Indicator | SBLK | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 73.32 |
| Support Level | $23.88 | $61.63 |
| Resistance Level | $27.81 | N/A |
| Average True Range (ATR) | 0.82 | 2.44 |
| MACD | -0.30 | 0.12 |
| Stochastic Oscillator | 12.45 | 90.72 |
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. The firm generates the majority of its revenue from Time charters and Voyage charters.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.